Efficacy of linezolid in the treatment of mediastinitis due to methicillin-resistant Staphylococcus aureus: an experimental study

International Journal of Infectious Diseases

Volumn 12, Issue 4, 2008, Pages 396-401

  Sacar, Mustafa ^a   Sacar, Suzan ^b   Kaleli, Ilknur ^b   Cevahir, Nural ^b   Teke, Zafer ^b   Kavas, Semra Toprak ^b   Asan, Ali ^b   Aytekin, Faruk Onder ^b   Baltalarli, Ahmet ^a   Turgut, Huseyin ^b  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Linezolid; Surgical site infection

Indexed keywords

LINEZOLID; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIUM CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EXPERIMENTAL STUDY; HUMAN; MALE; MEDIASTINITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; POSTOPERATIVE INFECTION; QUANTITATIVE ANALYSIS; RAT; STERNOTOMY; STERNUM; TREATMENT OUTCOME;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; MALE; MEDIASTINITIS; METHICILLIN RESISTANCE; OXAZOLIDINONES; RATS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURGICAL WOUND INFECTION;

EID: 44949153693     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.09.017     Document Type: Article

References (48)

1. Farinas M.C., Gald Peralta F., Bernal J.M., Rabasa J.M., Revuelta J.M., and Gonzalez-Macias J. Suppurative mediastinitis after open-heart surgery: a case-control study covering a seven-year period in Santander, Spain. Clin Infect Dis 20 (1995) 272-279
2. Gardlund B., Bitkover C., and Vaage J. Postoperative mediastinitis in cardiac surgery-microbiology and pathogenesis. Eur J Cardiothorac Surg 21 (2002) 825-830
3. Loop F.D., Lytle B.W., Cosgrove D.M., Mahfood S., McHenry M.C., Goormastic M., et al. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. Ann Thorac Surg 49 (1990) 179-186
4. Munoz P., Menasalvas J., de Quiros B., Desco M., Vallejo J., and Bouza E. Post-surgical mediastinitis: a case-control study. Clin Infect Dis 25 (1997) 1060-1064
5. Mekontso-Dessap A., Kirsch M., Brun-Buisson C., and Loisance D. Poststernotomy mediastinitis due to Staphylococcus aureus: comparison of methicillin-resistant and methicillin-susceptible cases. Clin Infect Dis 32 (2001) 877-883
6. Rupp M.E. Mediastinitis. In: Mandell G.L., Bennet J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 6th ed. (2005), Elsevier Churchill Livingstone, Philadelphia, Pennsylvania 1070-1078
7. De Feo M., Gregorio R., Della Corte A., Marra C., Amarelli C., Renzulli A., et al. Deep sternal wound infection: the role of early debridement surgery. Eur J Cardiothorac Surg 19 (2001) 811-816
8. Losanoff J.E., Richman B.W., and Jones J.W. Disruption and infection of median sternotomy: a comprehensive review. Eur J Cardiothorac Surg 21 (2002) 831-839
9. Schindler B. Worldwide spread of resistant Staphylococcus. Med Monatsschr Pharm 30 (2007) 155-156
10. Santos Sanches I., Mato R., de Lencastre H., Tomasz A., and CEM/NET Collaborators and the International Collaborators. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb Drug Resist 6 (2000) 199-211
11. Livermore D.M. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 51 (2003) 9-16
12. Rybak M.J., Hershberger E., Moldovan T., and Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 44 (2000) 1062-1066
13. Drlica K. A strategy for fighting antibiotic resistance. ASM News 67 (2001) 27-33
14. Koleff M.H., and Fraser V.J. Antibiotic resistance in the intensive care unit. Ann Intern Med 134 (2001) 298-314
15. Sano K., and Tunakawa N. Chemistry of rifampicin. Med Treatment 23 (1970) 928-935
16. Cepeda J.A., Whitehouse T., Cooper B., Hails J., Jones K., Kwaku F., et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 53 (2004) 345-355
17. Gander S., Hayward K., and Finch R. An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J Antimicrob Chemother 49 (2002) 301-308
18. Dailey C.F., Pagano P.J., Buchanan L.V., Paquette J.A., Haas J.V., and Gibson J.K. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 47 (2003) 2655-2658
19. Ford C.W., Hamel J.C., Wilson D.M., Moerman J.K., Stapert D., Yancey Jr. R.J., et al. In vivo activities of U-100592 and U-10076, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 40 (1996) 1508-1513
20. Institute of Laboratory Animal Resources National Research Council. Guide for the care and use of laboratory animals (1996), National Academy Press, Washington, DC
21. Kloos W.E., and Barnerman T.L. Staphylococcus and micrococcus. In: Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., and Yolken R.H. (Eds). Manual of clinical microbiology. 7th ed. (1999), ASM Press, Washington 264-277
22. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. M07-A7 (2006), Clinical and Laboratory Standards Institute, Wayne, PA
23. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. M26-A (1997), National Committee for Clinical Laboratory Standards, Wayne, PA
24. Kruse A.J., Peerdeman S.M., Bet P.M., and Debets-Ossenkopp Y.J. Successful treatment with linezolid and rifampicin of meningitis due to methicillin-resistant Staphylococcus epidermidis refractory to vancomycin treatment. Eur J Clin Microbiol Infect Dis 25 (2006) 135-137
25. Jacqueline C., Caillon J., Le Mabecque V., Miegeville A.F., Donnio P.Y., Bugnon D., et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin, or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 51 (2003) 857-864
26. Ersoz G., Aytacoglu B., Sucu N., Tamer L., Bayindir I., Kose N., et al. Comparison and evaluation of experimental mediastinitis model: precolonized foreign body implants and bacterial suspension inoculation seems promising. BMC Infect Dis 6 (2006) 76
27. Gentry-Nielsen M.J., Olsen K.M., and Preheim L.C. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother 46 (2002) 1345-1351
28. Slatter J.G., Adams L.A., Bush E.C., Chiba K., Daley-Yates P.T., Feenstra K.L., et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32 (2002) 907-924
29. Ogus T.N., Hulusi Us M., Cicek S., Ozkan S., Yuksel Ozturk O., and Isik O. Sternal cyanoacrylate gluing in mediastinitis. Effects on infection, stability and bone healing. J Cardiovasc Surg (Torino) 43 (2002) 741-746
30. Combes A., Trouillet J.L., Baudot J., Mokhtari M., Chastre J., and Gibert C. Is it possible to cure mediastinitis in patients with major postcardiac surgery complications?. Ann Thorac Surg 72 (2001) 1592-1597
31. Naylor A.R., Hayes P.D., and Darke S. A prospective audit of complex wound and graft infections in Great Britain and Ireland: the emergence of MRSA. Eur J Vasc Endovasc Surg 21 (2001) 289-294
32. Wilson W.R., Karchmer A.W., Dajani A.S., Taubert K.A., Bayer A., Kaye D., et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 274 (1995) 1706-1713
33. Foville Jr. R.J., Zaske D.E., Kaplan E.L., Crossley K., Sabath L.D., and Quie P.G. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA 240 (1978) 1963-1965
34. Pallares R., Dick R., Wenzel R.P., Adams J.R., and Nettleman M.D. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol 14 (1993) 376-382
35. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B., et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 340 (1999) 493-501
36. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., et al. Treatment outcomes for serious infections caused by Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 (2004) 521-528
37. Romero-Vivas J., Rubio M., Fernandez C., and Picazo J.J. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 21 (1995) 1417-1423
38. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., and Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34 (2002) 1481-1490
39. Dresser J.D., Birmingham M.C., Karchmer A.W., Rayner C.R., Falvin S.M., and Schentag J.J. Results of treating infective endocarditis with linezolid [abstract 2239]. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000), American Society for Microbiology, Washington, DC
40. Stalker D.J., Wajszczuk C.P., and Batts D.H. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days [abstract A115]. Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997), American Society for Microbiology, Washington, DC
41. Chiba K., Feenstra K.L., Slatter J.G., Daley-Yates P.T., Duncan J.N., Fagerness P.E., et al. Absorption, distribution, metabolism and excretion of the oxazolidinone antibiotic linezolid (PNU-100766) in the Sprague Dawley Rat [abstract A123]. Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (1998), American Society for Microbiology, Washington, DC
42. Jabes D., Candiani G., Romano G., Brunati C., Riva S., and Cavaleri M. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 48 (2004) 1118-1123
43. Stevens D., Dotter B., and Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2 (2004) 51-59
44. Oramas-Shirey M.P., Buchanan L.V., Dileto-Fang C.L., Dailey C.F., Ford C.W., Batts D.H., et al. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 47 (2001) 349-352
45. Corne P., Marchandin H., Macia J.C., and Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 37 (2005) 946-949
46. Diekema D.J., and Jones R.N. Oxazolidinone antibiotics. Lancet 358 (2001) 1975-1982
47. Meka V.G., Pillai S.K., Sakoulas G., Wennersten C., Venkataraman L., DeGirolami P.C., et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 190 (2004) 311-317
48. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., and Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 27 (2006) 300-302